Melbourne-based Amplia Therapeutics (ASX:ATX) announced a clinical breakthrough in the treatment of advanced pancreatic cancer, following a formal independent analysis of its Phase 1b/2a ACCENT trial.
The updated data reveals that five patients achieved a complete response—defined by the disappearance of all measurable tumours for at least two months—when treated with the company's lead drug, narmafotinib, in combination with standard chemotherapy.
This represents an unprecedented CR rate of 7.8% (5/64) for this notoriously difficult-to-treat indication, excluding a previously recorded pathological complete response from June 2025.
Beyond the disappearance of tumours, the trial demonstrated a median overall survival of 11.1 months, marking a two-month improvement over chemotherapy alone without adding any further toxicity burden to patients.
The independent "central read," conducted by a contracted laboratory using international RECIST 1.1 criteria, also identified an additional partial response, bringing the Objective Response Rate (ORR) to 35.9% (23/64).
As of mid-March, four patients remain on the study, with one individual approaching the two-year mark.
The results have earned the company a presentation slot at the American Association of Cancer Research annual meeting in San Diego this April.
With the ACCENT trial anticipated to reach completion in the third quarter of 2026, these findings suggest a promising new therapeutic path for patients facing limited options in the fight against pancreatic cancer.
At the time of reporting, Amplia Therapeutics' share price was $0.20.